AILERON THERAPEUTICS, INC.
285 Summer Street, Suite 101
Boston, Massachusetts 02210
June 14, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Aileron Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-265470
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aileron Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-265470), so that it may become effective at 4:30 p.m. Eastern time on June 16, 2022, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours, | ||
| AILERON THERAPEUTICS, INC. | ||
| By: | /s/ Manuel Aivado | |
| Name: | Manuel Aivado | |
| Title: | President and Chief Executive Officer | |
| cc: | Stuart Falber, Wilmer Cutler Pickering Hale and Dorr LLP |
Craig Hilts, Wilmer Cutler Pickering Hale and Dorr LLP